2m 2m 2m 2m 2m 2m 2m
Gilead Sciences (GILD)
NASDAQ
$125.54+$0.67 (+0.54%)
Price as of Jun 23, 2026 12:41 PM EDT- $155.0BMarket Cap
- 20.65%1-Year Change
- Drug Manufacturers - GeneralIndustry
Gilead Sciences (GILD)
$125.54+$0.67 (+0.54%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 28.9B +0.56% | 28.8B +6.04% | 27.1B -0.60% | 27.3B -0.09% | |
Cost of Revenue | 6.2B -0.27% | 6.3B -3.80% | 6.5B +14.87% | 5.7B -14.30% | |
Gross Profit | 22.7B +0.79% | 22.5B +9.14% | 20.6B -4.65% | 21.6B +4.44% | |
Sales and Marketing Expense | 5.8B -5.20% | 6.1B +0.02% | 6.1B +7.35% | 5.7B +8.14% | |
Research and Development Expense | -5.8B -1.83% | -5.9B +3.31% | -5.7B -3.43% | -5.9B +10.40% | |
Depreciation and Amortization Expense | 370.0M -2.89% | 381.0M +7.63% | 354.0M +9.60% | 323.0M -1.82% | |
Total Operating Expenses | 19.4B -28.31% | 27.1B +38.86% | 19.5B -2.21% | 20.0B +14.75% | |
Operating Profit | 10.0B +503.01% | 1.7B -78.15% | 7.6B +3.75% | 7.3B -26.09% | |
Interest Income | 349.0M +24.20% | 281.0M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -944.0M +0.96% | -935.0M -6.59% | |
Interest Income and Expense and Net | 349.0M +24.20% | 281.0M +129.77% | -944.0M +0.96% | -935.0M -6.59% | |
Total Nonoperating Income and Expense | 798.0M +13,200.00% | 6.0M -96.97% | 198.0M +134.08% | -581.0M -9.08% | |
Income before Taxes | 9.8B +1,319.71% | 690.0M -89.94% | 6.9B +17.97% | 5.8B -29.77% | |
Income Taxes | 1.3B +509.48% | 211.0M -83.08% | 1.2B -0.08% | 1.2B -39.91% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 8.5B +1,672.92% | 480.0M -91.53% | 5.7B +23.37% | 4.6B -26.23% | |
Net Income from Continuing Operations Applicable to Common | 9.8B +1,319.71% | 690.0M -89.94% | 6.9B +17.97% | 5.8B -29.77% | |
Basic EPS and Net Income | 6.84 +1,700.00% | 0.38 -91.63% | 4.54 +24.04% | 3.66 -26.21% | |
Diluted EPS and Net Income | 6.78 +1,684.21% | 0.38 -91.56% | 4.50 +23.63% | 3.64 -26.17% | |
Basic Weighted Average Shares | 1.2B -0.24% | 1.2B -0.08% | 1.2B -0.56% | 1.3B -0.08% | |
Diluted Weighted Average Shares | 1.3B 0.00% | 1.3B -0.24% | 1.3B -0.32% | 1.3B 0.00% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 7.6B -24.29% | 10.0B +64.19% | 6.1B +12.44% | 5.4B +1.39% | |
Short-Term Investments | 68.0M N/A | 0 -100.00% | 1.2B +21.17% | 973.0M -17.68% | |
Cash and Cash Equivalents and Short-Term Investments | 7.6B -23.61% | 10.0B +37.54% | 7.3B +13.77% | 6.4B -2.07% | |
Total Current Assets | 18.3B -4.33% | 19.2B +19.20% | 16.1B +11.37% | 14.4B -2.23% | |
Accumulated Depreciation | 2.7B +9.15% | 2.5B +0.86% | 2.4B +12.03% | 2.2B +15.48% | |
Property and Plant and Equipment and Net | 5.6B +3.55% | 5.4B +1.82% | 5.3B -2.89% | 5.5B +6.91% | |
Total Long-Term Assets | 4.8B -21.17% | 6.1B +28.26% | 4.8B -0.17% | 4.8B -3.28% | |
Total Assets | 59.0B +0.05% | 59.0B -5.04% | 62.1B -1.66% | 63.2B -7.04% | |
Income Taxes Payable | 1.3B -16.47% | 1.6B -57.15% | 3.6B -44.95% | 6.6B -27.78% | |
Total Short-Term Debt | 2.8B +54.66% | 1.8B +0.95% | 1.8B -20.90% | 2.3B +49.93% | |
Total Current Liabilities | 11.8B -1.59% | 12.0B +6.42% | 11.3B +0.38% | 11.2B -3.21% | |
Total Long-Term Debt | 22.1B -11.11% | 24.9B +7.36% | 23.2B +1.01% | 23.0B -8.82% | |
Total Long-Term Liabilities | 1.2B -10.04% | 1.3B +1.17% | 1.3B +8.57% | 1.2B +20.80% | |
Total Liabilities | 11.8B -1.59% | 12.0B +6.42% | 11.3B +0.38% | 11.2B -3.21% | |
Retained Earnings | 13.7B +19.42% | 11.5B -29.48% | 16.3B +3.93% | 15.7B -3.90% | |
Total Stockholders Equity | 22.7B +17.45% | 19.3B -15.34% | 22.8B +7.50% | 21.2B +0.81% | |
Total Shares Outstanding | 1.2B -0.40% | 1.2B 0.00% | 1.2B -0.08% | 1.2B -0.56% | |
Cash Flow | |||||
Cash from Operating Activities | 10.0B -7.47% | 10.8B +35.25% | 8.0B -11.75% | 9.1B -20.31% | |
Capital Expenditures | 563.0M +7.65% | 523.0M -10.60% | 585.0M -19.64% | 728.0M +25.73% | |
Cash from Investing Activities | -4.8B +38.97% | -3.4B +52.27% | -2.3B -8.15% | -2.5B -21.24% | |
Dividends Paid | 4.0B +2.17% | 3.9B +2.86% | 3.8B +2.70% | 3.7B +2.88% | |
Cash from Financing Activities | -7.7B +125.60% | -3.4B -33.01% | -5.1B -20.78% | -6.5B -27.13% | |
Financials Ratio | |||||
Gross Margin | 78.44% +0.23% | 78.26% +2.93% | 76.04% -4.07% | 79.26% +4.54% | |
Operating Margin | 34.66% +499.65% | 5.78% -79.39% | 28.05% +4.38% | 26.87% -26.03% | |
Return on Assets | 14.42% +1,719.52% | 0.79% -91.23% | 9.04% +29.10% | 7.00% -23.29% | |
Return on Equity | 40.49% +1,678.38% | 2.28% -91.14% | 25.71% +18.43% | 21.71% -31.53% | |
Revenue Growth | 0.56% -90.73% | 6.04% +1,098.79% | -0.60% +588.05% | -0.09% -100.83% | |
Current Ratio | 1.55 -2.79% | 1.60 +12.01% | 1.43 +10.95% | 1.29 +1.01% | |
Cash Ratio | 0.64 -23.07% | 0.83 +54.27% | 0.54 +12.02% | 0.48 +4.74% | |
Debt-to-Equity Ratio | 1.10 -20.51% | 1.38 +26.27% | 1.09 -7.88% | 1.19 -6.24% | |
Debt-to-Assets Ratio | 0.42 -6.69% | 0.45 +12.58% | 0.40 +0.70% | 0.40 +1.65% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow